PR Newswire Clinical TrialsOriginal article
New clinical evidence presented at PAINWeek 2026 demonstrates the powerful, long-lasting relief of TYLENOL® with Naproxen in post-surgical pain studies
Phase 3positiveTYLENOL® with NaproxenPositive
AI Analysis
Summary
Johnson & Johnson presented Phase 3 clinical data for TYLENOL® with Naproxen at PAINWeek 2026, demonstrating effectiveness as a non-opioid OTC option for post-surgical and persistent pain management based on two rigorous studies.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Two rigorous Phase 3 clinical studies demonstrated effectiveness of TYLENOL with Naproxen for post-surgical pain relief
Importance:5/10
Sentiment:
0.70
Phase 3 dataOTC pain managementnon-opioidPAINWeek 2026post-surgical indication
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 8, 2026 10:45 AM